MARIA BEATRIZ SARTOR DE FARIA
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
7 resultados
Resultados de Busca
Agora exibindo 1 - 7 de 7
- Polypropylene and polypropylene/polyglecaprone (Ultrapro(r)) meshes in the repair of incisional hernia in rats(2015) UTIYAMA, Edivaldo Massazo; ROSA, Maria Beatriz Sartor de Faria; ANDRES, Marina de Paula; MIRANDA, Jocielle Santos de; DAMOUS, Sérgio Henrique Bastos; BIROLINI, Cláudio Augusto Vianna; DAMOUS, Luciana Lamarão; MONTERO, Edna Frasson de SouzaPURPOSE: To compare the inflammatory response of three different meshes on abdominal hernia repair in an experimental model of incisional hernia. METHODS: Median fascial incision and skin synthesis was performed on 30 Wistar rats. After 21 days, abdominal hernia developed was corrected as follows: 1) No mesh; 2) Polypropylene mesh; and, 3) Ultrapro(r) mesh. After 21 days, the mesh and surrounding tissue were submitted to macroscopic (presence of adhesions, mesh retraction), microscopic analysis to identify and quantify the inflammatory and fibrotic response using a score based on a predefined scale of 0-3 degrees, evaluating infiltration of macrophages, giant cells, neutrophils and lymphocytes. RESULTS: No significant difference was seen among groups in adherences, fibrosis, giant cells, macrophages, neutrophils or lymphocytes (p>0.05). Mesh shrinkage was observed in all groups, but also no difference was observed between polypropylene and Ultrapro mesh (7.0±9.9 vs. 7.4±10.1, respectively, p=0.967). Post-operatory complications included fistula, abscess, dehiscence, serohematic collection and reherniation, but with no difference among groups (p=0.363). CONCLUSION: There is no difference between polypropylene (high-density) and Ultrapro(r) (low-density) meshes at 21 days after surgery in extraperitoneal use in rats, comparing inflammatory response, mesh shortening, adhesions or complications.
- B lymphocytes can be activated to act as antigen presenting cells to promote anti-tumor responses(2018) ROSSETTI, Renata Ariza Marques; LORENZI, Noely Paula Cristina; YOKOCHI, Kaori; ROSA, Maria Beatriz Sartor de Faria; BENEVIDES, Luciana; MARGARIDO, Paulo Francisco Ramos; BARACAT, Edmund Chada; CARVALHO, Jesus Paula; VILLA, Luisa Lina; LEPIQUE, Ana PaulaImmune evasion by tumors includes several different mechanisms, including the inefficiency of antigen presenting cells (APCs) to trigger anti-tumor T cell responses. B lymphocytes may display a pro-tumoral role but can also be modulated to function as antigen presenting cells to T lymphocytes, capable of triggering anti-cancer immune responses. While dendritic cells, DCs, are the best APC population to activate naive T cells, DCs or their precursors, monocytes, are frequently modulated by tumors, displaying a tolerogenic phenotype in cancer patients. In patients with cervical cancer, we observed that monocyte derived DCs are tolerogenic, inhibiting allogeneic T cell activation compared to the same population obtained from patients with precursor lesions or cervicitis. In this work, we show that B lymphocytes from cervical cancer patients respond to treatment with sCD40L and IL-4 by increasing the CD80(+)CD86(+) population, therefore potentially increasing their ability to activate T cells. To test if B lymphocytes could actually trigger anti-tumor T cell responses, we designed an experimental model where we harvested T and B lymphocytes, or dendritic cells, from tumor bearing donors, and after APC stimulation, transplanted them, together with T cells into RAG1(-/-) recipients, previously injected with tumor cells. We were able to show that anti-CD40 activated B lymphocytes could trigger secondary T cell responses, dependent on MHC-II expression. Moreover, we showed that dendritic cells were resistant to the anti-CD40 treatment and unable to stimulate anti-tumor responses. In summary, our results suggest that B lymphocytes may be used as a tool for immunotherapy against cancer.
- Secondary healing strategy for difficult wound closure in invasive vulvar cancer: a pilot case-control study(2019) DIAS-JR, Altamiro Ribeiro; SOARES-JR, Jose Maria; FARIA, Maria Beatriz Sartor de; GENTA, Maria Luiza Noqueira Dias; CARVALHO, Jesus Paula; BARACAT, Edmund C.OBJECTIVES: Despite the number of surgical advances and innovations in techniques over time, radical vulvectomy frequently results in substantial loss of tissue that cannot be primarily closed without tension, the mobilization of surrounding tissues or even the rotation of myocutaneous flaps. The aim of this study was to evaluate the feasibility of leaving the surgical vulvar open wound for secondary healing in situations where primary closure of the vulvar wound is not possible. METHODS: This case-control pilot study analyzed 16 women with a diagnosis of squamous cell carcinoma of the vulva who first underwent inguinofemoral lymphadenectomy, 6-week sessions of chemotherapy and 25 daily sessions of radiotherapy. Afterward, excision of the vulvar lesion with free margins was performed between January 2011 and July 2017. Twelve patients underwent primary closure of the wound (control), and in 4 patients, the surgical wound was left open for secondary healing by means of a hydrofiber (case). The inclusion criteria were a) FIGO-2009 stage II up to IIIC; b) squamous cell carcinoma; and c) no evidence of pelvic or extrapelvic disease or pelvic nodal involvement. The exclusion criteria were extrapelvic disease or pelvic nodal involvement, another primary cancer, or a poor clinical condition. ClinicalTrials.gov: NCT02067052. RESULTS: The mean age of the patients at the time of the intervention was 62.1. The distribution of the stages was as follows: II, n=6 (37 %); IIIA, n=1 (6%), IIIB, n=1 (6%) and IIIC, n=8 (51%). The mean operative time was 45 minutes. The hospital stay duration was 2 days. Full vulvar healing occurred after an average of 30 days in the control group and after an average of 50 days in the case group. CONCLUSION: A secondary healing strategy may be an option for the treatment of vulvar cancer in situations of non-extensive surgical wounds when primary closure of the wound is not possible.
- TOXICITY PROFILE IN PATIENTS SUBMITTED TO NEW STRATEGY FOR THE TREATMENT OF VULVAR CANCER EMPLOYING SENTINEL LYMPH NODE SCINTIGRAPHY, SURGERY, CHEMOTHERAPY, AND RADIOTHERAPY(2019) DIAS- JR., A.; NAJAS, G.; GABRIELLI, F.; CARVALHO, H.; MIGLINO, G.; FARIA, M. B. Sartor; ARAUJO, M.; GENTA, M. L. Nogueira Dias; CARVALHO, J. Paula; BARACAT, E. Chada
- ARE THE COMPLICATIONS AFTER LYMPH NODE GROIN DISSECTION FOR THE TREATMENT OF VULVAR CANCER CORRELATED TO DRAINAGE SYSTEM? COMPARISON OF SILICONIZED PENROSE AND PORTO VAC(2019) DIAS- JR., A.; FARIA, M. B. Sartor; SIGNORINI FILHO, R. Cesar; KLEINE, R. Truffa; ENNES, A. Luis Costa; MICELLI, L. Pizzinatto; SANDON, L. Souza; WAGNER, M.; MAYERHOFF, E. Vieira Luna; CARVALHO, J. Paula; BARACAT, E. Chada
conferenceObject Successful Live Birth in a Female with 17-Hydroxylase Deficiency through IVF Frozen-Thawed Embryo Transfer after Adequate Endometrial Preparation(2014) BIANCHI, Paulo H. M.; GOUVEIA, Gabriela R. F. C. A.; DOMENICE, Sorahia; COSTA, Elaine M. F.; MARTIN, Regina M.; CARVALHO, Luciane C.; PELAES, Tatiana S.; CODARIN, Rodrigo R.; FARIA, Maria Beatriz S.; FRANCISCO, Rossana P. V.; BARACAT, Edmund Chada; SERAFINI, Paulo C.; MENDONCA, Berenice B.- Successful Live Birth in a Woman With 17 alpha-Hydroxylase Deficiency Through IVF Frozen-Thawed Embryo Transfer(2016) BIANCHI, Paulo Homem de Mello; GOUVEIA, Gabriela Romanenghi Fanti Carvalho Araujo; COSTA, Elaine M. Frade; DOMENICE, Sorahia; MARTIN, Regina M.; CARVALHO, Luciane Carneiro de; PELAES, Tatiana; INACIO, Marlene; CODARIN, Rodrigo Rocha; FARIA, Maria Beatriz Sator de; FRANCISCO, Rossana Pulcineli Vieira; BARACAT, Edmund Chada; SERAFINI, Paulo Cesar; MENDONCA, Berenice B.Context: Congenital adrenal hyperplasia (CAH) dueto 17 alpha-hydroxylase deficiency in 46,XX patients is characterized by primary amenorrhea, absent or incomplete sexual maturation, infertility, low serum levels of estradiol, and elevated progesterone (P). There were no previous reports of singleton live births from such women. Objective: To describe the first successful singleton live birth in a female with CAH due to 17 alpha-hydroxylase deficiency. Case Description: A 26-year-old Brazilian woman with CAH associated with 17 alpha-hydroxylase deficiency due to the compound heterozygote mutation (p.W406R/P428L) in the CYP17A1 gene expressed the desire to conceive. In vitro fertilization (IVF) was recommended due to the complexity of the disorder. The first attempt of treatment failed despite the production of viable embryos. At the second IVF attempt, all viable embryos were frozen due to inadequate endometrial development associated with prematurely elevated serum P during ovarian stimulation. Subsequently, a long-acting GnRH agonist and oral dexamethasone were used to lower ovarian and adrenal P overproduction. Once serum levels of P were < 1 ng/mL, endometrial preparation with estradiol valerate and frozen-thawed embryo transfer were performed, resulting in a singleton pregnancy. Estradiol supplementation was completely suspended by 14 weeks of gestation. She delivered at 30 weeks and 4 days due to acute fetal distress. The puerperium was uneventful; the newborn was discharged in good conditions 5 weeks after birth. Conclusion: A successful live birth was achieved in a woman with 17-hydroxylase deficiency through IVF, cryopreservation of all embryos, and frozen-thawed embryo transfer after adequate endometrial preparation.